S1005, “A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer”
The primary aim of this study is to find out what effects,good and/or bad, the study drug MK-2206 has on subjects with gastric or gastroesophageal (GE) junction cancer.
* Cancer of Stomach or between Stomach and Esophagus (Gastroesophageal Junction)
* Must have prior chemotherapy which led to progression, or a recurrence.
* No chemotherapy or radiotherapy within 3 weeks prior to registration
18 - 99
Healthy Volunteers Needed
Duration of Participation
Participants will continue to take the study drug until their disease gets worse or the side effects become too bad.
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org